High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas

TCTP as therapeutic target in cancers

(2014) Julie Acunzo et al.   CANCER TREATMENT REVIEWS

Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

(2013) Richard Gorlick et al.   PEDIATRIC BLOOD & CANCER

Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors

(2013) Todd M. Pitts et al.   PHARMACOLOGY & THERAPEUTICS

Prognostic significance of phospho-histone H3 in prostate carcinoma

(2013) Michael Nowak et al.   WORLD JOURNAL OF UROLOGY

Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer

(2012) Einar Gudlaugsson et al.   HISTOPATHOLOGY

Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

(2012) Julie R. Park et al.   PEDIATRIC BLOOD & CANCER

An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies

(2011) Kristina Spaniol et al.   ANTI-CANCER DRUGS

Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells

(2011) Natalie Grinshtein et al.   CANCER RESEARCH

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

(2011) A. Faisal et al.   MOLECULAR CANCER THERAPEUTICS

Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma

(2010) S. Ackermann et al.   CLINICAL CANCER RESEARCH

Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer

(2009) M Loddo et al.   BRITISH JOURNAL OF CANCER

Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma

(2009) X. Shang et al.   MOLECULAR CANCER THERAPEUTICS

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY